Amphivena closes $62m Series C financing to expand clinical development of AMV564 into solid tumors and to develop T Cell engagement portfolio

This article was originally published here

The round was co-led by NanoDimension and Qiming Venture Partners USA, and included new investors Clough Capital, Aju IB, Korys Merieux, Kaitai Capital, Industrial Investors, Nawton Limited and

The post Amphivena closes $62m Series C financing to expand clinical development of AMV564 into solid tumors and to develop T Cell engagement portfolio appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply